Back to Search
Start Over
Daiichi Sankyo & AstraZeneca's Datroway gets US FDA approval for patients with previously treated metastatic HR positive, HER2 negative breast cancer
- Source :
- PharmaBiz. January 20, 2025
- Publication Year :
- 2025
-
Abstract
- Datroway (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.824196493